Treatment options for children with fusion-driven Alveolar Rhabdomyosarcoma (aRMS) are very limited, and there are no approved new targeted therapy approaches for these children. In fact, there have been no substantial improvements in treatments for these children in over two decades. I have identified CDK8 as a candidate therapeutic target in aRMS and interaction partner of PAX3-FOXO1, the abnormal gene involved in the initiation and maintenance of this disease.